Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912)

TO THE EDITOR: We read with interest the publication by van Poppelen et al1 that argue iris melanomas are pathogenetically closely related to uveal melanoma is similar to our prior findings.3 All mutations known to be activating were detected in GNAQ and GNA11. Additionally, the co-occurring mutations in EIF1AX, SF3B1, and BAP1 are reminiscent of the mutations seen in posterior uveal melanoma.3 In our opinion, the nature of the other mutations identified in BRAF, NRAS, KIT, PTEN, and TP53 argues for these being non-pathogenic passenger mutations. The classification of iris melanoma as pathogenetically related to intraocular ciliary and choroidal melanoma and not to melanomas of the ocular surface and the skin could prove important for optimal management of affected patients.

SIMONE L. SCHOLZ, MD 1,4
RAIMO MURALI, MD 1,4
HENRIK WESTEKEMPER, MD 1
DIRK SCHADENDORF, MD 1
KL AUS G. GRIEWANK, MD 3,4

1Department of Ophthalmology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany; 2Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; 3Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany; 4Dermatopathologie bei Mainz, Nieder-Olm, Germany

*S.L.S. and R.M. contributed equally to this work.

Financial Disclosures: The authors made the following disclosures: K.G.G.: Co-inventor — Gna11 and gnaq exon 4 mutations in melanoma (license). D.S.: Personal fees — Amgen, Boehringer Ingelheim, Leo Pharma, Roche; Novartis, Incyte, Regeneron, 4SC, AstraZeneca, BMS, Pierre Fabre, Merck-EMD, Pfizer, Philoingen, Array, MSD; Other — Roche; Novartis, Regeneron, BMD, Merck-EMD, Philoingen, MSD; all outside the submitted work.

Available online: ■■■■

Correspondence:
Klaus G. Griewank, MD, Department of Dermatology, Hufelandstrasse 55, Essen 45147, Germany. E-mail: klaus.griewank@uk-essen.de.

References


*